Blood pressure elevation is likely a pharmacodynamic marker of VEGF signaling pathway (VSP) inhibition and could be useful for optimizing safe and effective VSP inhibitor dosing. Blood pressure rises on the first day of treatment, facilitating design and interpretation of future trials aiming to correlate blood pressure changes with clinical outcomes.

Original languageEnglish
Pages (from-to)5947-5949
Number of pages3
JournalClinical Cancer Research
Issue number19
StatePublished - Oct 1 2009


Dive into the research topics of 'Rapid development of hypertension by sorafenib: Toxicity or target?'. Together they form a unique fingerprint.

Cite this